.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AA02_Filgrastim.Filgrastim

Information

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils. It is used for the prevention and treatment of neutropenia in patients undergoing chemotherapy, bone marrow transplantation, or with severe chronic neutropenia. Filgrastim is approved and in current clinical use.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after subcutaneous administration. Typical patient population: adult, healthy, both sexes.

References

1. Wiczling, P, et al., & Krzyzanski, W (2009). Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clinical pharmacokinetics 48(12) 817–826. DOI:10.2165/11318090-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19902989

2. Krzyzanski, W, et al., & Balser, S (2010). Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. Journal of clinical pharmacology 50(9 Suppl) 101S–112S. DOI:10.1177/0091270010376966 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20881223

3. Wang, B, et al., & Roskos, LK (2001). Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. Journal of pharmacokinetics and pharmacodynamics 28(4) 321–342. DOI:10.1023/a:1011534529622 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11677930

Revisions

• 06/2025 initial generated model